Insulin therapy in type 2 diabetes;L'Insulinothérapie dans le diabète de type 2

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 419-423

  Philips, Jean Christophe ^a   Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Insulin analogues; Insulin therapy; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE;

GLUCOSE BLOOD LEVEL; HUMAN; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS;

EID: 21744461471     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Féry F, Paquot N.- Etiopathogénie et physiopathologie du diabète de type 2. Rev Med Liège, 2005, 60, 361-368.
2. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique: plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
3. Scheen AJ, Lefèbvre PJ.- Le diabète non insulinodépendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg, 1996, 151, 395-405.
4. UKPDS Group.- Sulphonylurea inadequacy. Efficacy of addition of insulin over 6 year in patients with type 2 diabetes (UKPDS 57). Diabetes Care, 2002, 25, 330-336.
5. Philips J-C, Radermecker JAP.- L'insulinothérapie dans le diabète de type 1. Rev Med Liège, 2005, 60, 322-328.
6. Davis T, Edelman S.- Insulin therapy in type 2 diabetes. Med Clin North Am, 2004, 88, 865-895.
7. Gerstein HC, Rosenstock J.- Insulin therapy in people who have dysglycemia and type 2 diabetes: can we offer both cardiovascular protection and beta-cell preservation? Endocrinol Metab Clin North Am, 2005, 34, 137-154.
8. Radermecker RP.- Le risque hypoglycémique: implications thérapeutiques. Rev Med Liège, 2005, 60, 461-465.
9. UKPDS Group.- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
10. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al.- Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. New Engl J Med, 1992, 327, 1426-1433.
11. Yki-Jarvinen H, Ryysy L, Nikkila K, et al.- Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Int Med, 1999, 130, 389-396.
12. Oiknine R, Bernbaum M, Mooradian AD.- A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs, 2005, 65, 325-340.
13. Riddle M, Rosenstock J, Gerich J, et al.- The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003, 26, 3080-3086.
14. Janka H, Plewe G, Riddle M, et al.- Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes. Diabetes Care, 2005, 28, 254-259.
15. Raskin, P, Allen E, Hollander P, et al.- Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care, 2005, 28, 260-265.
16. Yki-Järvinen H, Häring H-U, Johnson E, et al.- The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes (Abstract). Diabetes, 2003, 52 (suppl 1), A159-150.
17. Hermansen K, Derezinski T, Kim H, Gall M-A.- Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes (Abstract). Diabetologia, 2004, 47 (suppl 1), A273-274
18. The Oxford Centre for Diabetes, Endocrinology and Metabolism. Diabetes Trial Unit http:/www.dtu.ox.ac.uk/4-T.
19. Nobels F, Scheen AJ.- Le rôle des centres de convention du diabète en Belgique. Rev Med Liège, 2005, 60, 619-623.
20. Duysinx B, Scheen AJ, Paquot N, et al.- Le diabète de type 2 insulinorequérant: caractéristiques des patients et effets de l'insulinothérapie. Rev Med Liège, 1994, 49, 305-323.
21. Davidson M.- Starting Insulta Therapy in Type 2 Diabetic Patients: Does it really matter how? Diabetes Care, 2005, 28, 494-495.